Denali Therapeutics Inc (NASDAQ:DNLI)
| 74.93 BATS BZX Real-Time Price As of 2:41pm ET |  +1.33 / +1.81%Today’s Change | 22.36 Today|||52-Week Range 93.94 | -10.54% Year-to-Date |
Latest DNLI News | Press Releases
| Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal Jun 15 / Zacks.com - Paid Partner Content | Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming? Jun 15 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 73.60 |
| Today’s open | 73.57 |
| Day’s range | 73.48 - 75.00 |
| Volume | 12,442 |
| Average volume (3 months) | 554,690 |
| Market cap | $9.1B |
Data as of 2:41pm ET, 06/17/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -388.66% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +1,158.19% |
| P/E ratio | 124.9 |
| Price/Sales | 28.12 |
| Price/Book | 7.86 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IBRXImmunitybio Inc | -0.37 | -2.59% |
| ---- | ||
| TLRYTilray Inc | -0.30 | -1.65% |
| HALOHalozyme Therapeutic... | -0.19 | -0.44% |
Data as of 2:41pm ET, 06/17/2021
Financials
| Next reporting date | August 12, 2021 |
| EPS forecast (this quarter) | -$0.41 |
| Annual revenue (last year) | $335.7M |
| Annual profit (last year) | $71.1M |
| Net profit margin | 21.19% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Francisco, California |
Forecasts
